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Abstract
Down syndrome (DS) is associated with aberrations in genetic, morphological,
biochemical and physiological characteristics. A number of genes located on human
chromosome 21 (HSA21) encode proteins which are thought to be involved in
numerous metabolic pathways, e.g., phosphofructokinase, cystathionine β-synthase
etc. Perturbations of the metabolic pathways may lead to altered drug metabolism in
DS individuals. We present a review of metabolic aberrations linked to HSA21 genes
in DS. We particularly focus on drug disposition, efficacy, sensitivity and toxicity of
anti-leukaemic agents including methotrexate, glucocorticoids, anthracyclines and
cytarabine in DS leukaemia. The different outcomes of therapy due to differential drug
response, varied drug toxicity and treatment related mortality in DS leukaemia is a
subject of much research and speculation. Altered drug response in DS individuals
may stem from differences in pharmacokinetics, pharmacodynamics and pharmaco‐
genetics. Further large-cohort studies in different age groups dissecting metabolic and
molecular pathways involved in drug response may increase our understanding in
this regard and stipulate pharmacotherapies in DS.
Keywords: Down Syndrome, Drug Metabolism, Pharmacokinetics, Pharmacody‐
namics, Methotrexate, Leukaemia, Glucocorticoids, Anthracyclines, Cytarabine
1. Introduction
Down syndrome (DS) is the most commonly reported genetic disorder characterized by
intellectual disability which occurs in approximately 1/700 live births [1]. Despite advances in
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antenatal screening and pregnancy termination, the prevalence of DS is increasing due to
advanced maternal age and increased longevity of DS individuals [2-4]. Trisomy of all or part
of human chromosome 21 (HSA21) is the underlying genetic abnormality that causes DS. Some
200-300 genes have been identified to be located on the long arm as well as on a portion of the
short arm of chromosome 21 in DNA sequencing studies [5]. The overexpression of such genes
likely results in cascading effects, eliciting interactions among gene products and between
genes and environmental factors. These cause aberrations in the morphological, biochemical
and physiological milieu of DS individuals resulting in the characteristic manifestations of DS.
Down syndrome Individuals exhibit altered metabolism which is attributed to the overex‐
pression of some HSA21 localized genes or due to the presence of extra genetic information.
A number of genes located on HSA21 encode enzymes those are thought to be involved in
numerous metabolic pathways such as inositol, energy, cholesterol, choline, purine and
reactive oxygen species pathways [6]. In this chapter, we review the literature for characteristic
metabolic aberrations linked to HSA21 genes in DS. We particularly focus on the efficacy of
chemotherapeutic agents such as methotrexate, glucocorticoids, anthracyclines and cytarabine
in the context of drug disposition, sensitivity and toxicity in DS individuals since these agents
form the backbone of current anti-leukaemic therapies.
2. Gene-dosage effects
Several genes involved in metabolism are located on chromosome 21 such as cystathionine β-
synthase (CBS) gene encoding the CBS enzyme that catalyses homocysteine into cystathionine.
Due to the presence of an extra copy of CBS gene in DS individual, lower levels of homocysteine
and methionine are found in DS individuals compared to normal people which in turn leads
to folate shortage and an altered metabolic state. Formimidoyltransferase cyclodeaminase
(FTCD) is another gene located on the long arm of chromosome 21 which provides instruction
to produce formimimotransferase cyclodeaminase enzyme involved in the metabolism of
histidine and the production of folate required for synthesis of purine, pyrimidines and amino
acids. Variations in the activities of various enzymes and plasma electrolyte concentrations to
differ from normal parameters in DS have previously been reported especially in HSA 21
associated proteins such as S100B [7]. The levels of S100B protein were 4-8 times higher in DS
individuals compared to the reference values. In addition, changes in metabolism of adenosine,
homocysteine, purine and folate have also been reported [6].
Phosphofructokinase (PFK) is a key regulatory enzyme in glycolytic pathway as it catalyses
the phosphorylation of fructose-6-phospate to fructose-1, 6-bisphosphate [8]. Liver-type
subunit of PFK (PFKL) is overexpressed in DS patients because its gene is located on chromo‐
some 21 [9, 10]. Peled-Kamar et al. showed that transgenic mice overexpressing PFKL (Tg-
PFKL) had aberrated glucose metabolism characterized by increases metabolic rate in brain
and reduced clearance rate from the blood [11]. The enhanced glucose utilization observed in
brain of Tg-PFKL mice is similar to faster cerebral glucose metabolism exhibited by young DS
adults and may be linked to their cognitive disabilities. A previous study reported that PFK
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specific activity is increased two-fold in the brains of embryonic Tg-PFKL mice [12] highlight‐
ing the fact that aberration in glucose metabolism are more pronounced in developmental
period and may lead to DS associated learning disabilities. This observation of differential gene
expression at different developmental stages further complicates the hypothesis of ‘gene-
dosage effects’ in trisomy 21 consequently leading to varied metabolism aberration among
different age groups. Further studies to determine metabolic variations in different age groups
will not only increase our understanding in this regard but will also stipulate pharmacothera‐
pies in DS.
3. Drug metabolism in Down syndrome
The effect of perturbations in metabolic pathways in DS is also reflected in the area of drug
metabolism. Altered drug response has been reported in DS individuals compared to normal
people, which may stem from differences in pharmacokinetics (PK) and pharmacodynamics
(PD) in DS. Drug metabolizing enzymes, especially cytochrome P450, are a major source of
variability in the PK of drugs. The CYP3A subfamily is believed to metabolize half of all
prescribed drugs. Differences in the activity of cytochrome P450 may explain the altered drug
response in DS individuals. We studied the CYP3A4/5 activity and found that children with
DS had a 2.4 fold lower CYP3A4/5 activity compared to the children without DS (unpublished
data). Alterations in PD have been reported for opioids, midazolam, acetylsalicylic acid and
atropine [6, 13]. The metabolism of drugs is known to influence the active drug concentration
of a drug, which either boosts or causes a reduced action of that drug. A drug which is subjected
to increased metabolism will have a diminished intensity of drug action, as an increased
metabolism will limit its duration of activity. On the contrary, a decline in the metabolism of
the drug will intensify drug activity. Down syndrome individuals have a lower resting
metabolic rate compared to normal people, which may contribute to altered drug metabolism
and drug toxicity. Gut microbial chemical messengers regulate and influence host metabolism.
Differences in gut microbiome may also be a relevant factor in altered drug metabolism in DS
individuals and a review of literature is needed in this regard.
Down syndrome children are known to have an approximately 10- 20 times higher risk of
developing some blood cancers such as acute lymphoblastic leukaemia (ALL) and acute
myeloid leukaemia (AML) compared to non-DS children [14, 15]. In the last two decades,
numerous studies have identified various drugs showing altered metabolism in DS patients
in the context of childhood leukaemias. For instance, DS children suffering from AML have a
better prognosis over non-DS children with AML. An in vitro study showed that DS-AML
myeloblasts exhibited ten times higher sensitivity towards 1-beta-D-arabinofuranosylcytosine
(ara-C), compared to myeloblasts from non-DS AML children [16]. On the other hand DS
children with ALL show a pronounced intolerance for methotrexate which necessitates dose
reductions and further adjustments in treatment protocols.
As described above, DS individuals have a high risk of developing haematological conditions,
of which the most prominent is the development of acute leukaemias [17]. Acute lymphoid
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leukaemia (ALL), acute myeloid leukaemia (AML) and a unique type of leukaemia exclusively
associated with trisomy 21 called transient myeloproliferative disorder (TMD), commonly
arise in DS individuals [18]. It has been recognized that while the presence of chromosome 21
trisomy on the one hand might be a deterrent against development of certain solid tumours
in DS individuals, on the other hand it compounds the risk of development of haematological
tumours [17]. Of note, is the fact that the acute leukaemias in DS shows marked differences
from acute leukaemias in non-DS individuals. This varied picture reflects the underlying
change, which ranges from molecular to systems level in DS individuals and confers unique
characteristics to host and disease biology including marked differences in disease outcomes
as compared to non-DS leukaemia patients. The different outcomes of therapy due to differ‐
ential drug response, varied drug toxicity and treatment related mortality (TRM) remains in
DS leukaemia a subject of much research and speculation. In this connection, various studies
in the last two decades have highlighted the direct or indirect involvement of the extra copy
of chromosome 21 with its gene dosage imbalances as a basic factor [19]. Additionally, acute
leukaemia is known to be a highly heterogeneous disease [20, 21]. In DS patients with their
characteristic biochemical and pathophysiological state it most likely contributes to the
distinctive malignancy pattern observed in them.
Recent studies have identified new subtypes of DS leukaemia patients [22, 23].  The sub‐
types show distinctive prognostic features which also have a bearing on event free survival
(EFS) rates. This brings into perspective the issue of present drugs commonly used for the
treatment of leukaemia in DS, their metabolism and treatment outcomes. In this respect,
studies linking the genes or  possible  candidate genes involved,  the molecular  pathways
influenced by these genes, the gene products, the pathophysiologic milieu of DS leukaemia
and  the  pharmacological  differences  emerging  thereof  have  begun  to  clarify  the  drug
sensitivity, drug responsiveness and drug toxicity profiles in the setting of DS leukaemia.
This has resulted in protocol modifications in certain cases of DS leukaemia and improved
treatment outcomes [24, 25]. Patients’ response to a particular therapeutic regimen and the
drugs  concerned happens  to  be  the  most  crucial  prognostic  predictor  of  treatment  out‐
comes. In this context both malignant cell genetics and patients’ pharmacodynamics and
pharmacogenetics are intimately involved [26].
Studies in drug pharmacodynamics and pharmacokinetics have been helpful in informing and
formulating treatment regimens in DS and NDS leukaemia patients. Pharmacogenetics and
pharmacogenomics deals with the effect of a particular gene or genome wide associations
respectively on drug response of an individual [27]. Pharmacogenomics is a relatively new
and promising area which has the potential to unravel the enigmatic issues associated with
DS leukaemia. Altered metabolism of drugs is well recognized in cancers including leukaemia
and DS leukaemia [28-30]. High to severe drug related toxicity in ALLDS patients is a known
phenomenon. The toxicities may be related to the gastrointestinal mucosa, infectious toxicity
secondary to MTX use, haematological toxicity and hepatic toxicity, which under severe
circumstances may lead to liver fibrosis and neurological toxicity [31]. Besides, ALLDS patients
exhibit a higher level of resistance to certain drugs used in various chemotherapeutic regimens
than ALLNDS individuals.
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In DS individuals, more data are present for anti-leukaemic agents than any other drug.
Therefore, we present a detailed review of methotrexate, glucocorticoids, anthracyclines and
cytarabine in the next section.
4. Methotrexate
Methotrexate (MTX), an anti-folate agent [19] is one of the most widely used and frequently
studied drugs in various malignancies including leukaemia [22]. In ALL, the drug is usually
administered as high dose MTX (HDMTX) which constitutes 500mg/m2 and above. It is an
anti-metabolite that inhibits cellular growth by obstructing the formation of purines and
thymidine phosphate. MTX is known as a competitive inhibitor of dihydrofolate reductase,
(DHFR), an enzyme required for the conversion of terahydrofolate from dihydrofolate in
dividing cells. MTX competitively binds to DHFR, replacing dihydrofolate. This results in the
lack of regeneration of tetrahydrofolate, a reduced folate that is essential for de novo purine
and thymidine phosphate synthesis. This eventually blocks DNA synthesis [32-34].
MTX entry into the cell is facilitated by the reduced folate carrier (RFC) protein, which also
transports dihydrofolate, 5-methyl tetrahydrofolate and folinic acid [35].The gene for RFC
protein is localized on chromosome 21q22, so an increased gene dosage effect as a result of
chromosome 21 in DS, likely leads to entry and accumulation of higher amounts of MTX
with subsequent formation of MTX polyglutamates. The increased accumulation of MTX
polyglutamates in cells can be a marker of MTX toxicity [36]. Since every somatic cell in DS
patients  has  an  extra  copy  of  chromosome  21  (constitutional  trisomy),  increased  MTX
absorption in ALLDS, especially in the GI tract, may be responsible for the severe toxicity to
methotrexate observed in such patients [28, 30]. Polymorphisms in several genes concerned
with  folate  metabolism  and  their  association  with  MTX-generated  toxicity  have  been
identified. A retrospective study of 81 ALL children who had received treatment in keep‐
ing with the Dutch Childhood Oncology Group (DCOG) ALL-9 protocol, was conducted by
Huang et al. The therapeutic regimen included high dose methotrexate (HDMTX) administra‐
tion continuously as an IV infusion for a 24-hour period followed by leucovorin rescue in
three  doses.  The  results  indicated  that  patients  with  methylenetetrahydrofolate  reductase
(MTHFR) 1298 AC and CC and serine hydroxymethyl transferase (SHMT) 1420 CT genotypes
showed less toxicity to MTX, whereas methionine synthase reductase MTRR 66 AG and GG
genotypes exhibited higher toxicity [37].
A spectrum of side effects may arise from methotrexate use. Patient-to-patient variations have
also been recognized. The common side effects with increased frequency and severity in DS
individuals are mucositis, nausea and vomiting, diarrhoea, myelosuppression and hepatic
toxicity marked by perturbations in liver enzymes (transaminases). Coagulation and pancre‐
atic toxicities have also been reported after augmentation of methotrexate dose in post-
induction phases [38]. Additionally, central nervous system (CNS) toxicity, which may
precipitate in learning disabilities of a more complex and intractable nature in ALLDS than in
AMLDS, has been identified [39].
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An important strategy to reduce MTX toxicity is the administration of folinic acid (Leucovorin)
usually between 24 and 36 hours after administering HDMTX. Leucovorin selectively rescues
the normal cell from the adverse effects of methotrexate by restoring reduced folates in the
normal cells so that they use it in the formation of purines and thymidine phosphate [40]. In
an earlier study, Peters and Poon described methotrexate sensitivity in four patients with DS
leukaemia who had received MTX in the course of treatment [41]. Severe and immediate toxic
effects such as rash, diarrhoea and mucositis were detected in them irrespective mode of drug
administration i.e., intravenously, intrathecally or orally. The drug became tolerable after
dosing was considerably reduced (30%-50%). However, methotrexate absorption and clear‐
ance was within normal parameters in the two patients who were evaluated for it. The authors
suggested the possible involvement of enzymes synthesized by genes on chromosome 21
related to purine metabolism such as tetrahydrofolate [41]. In the Medical Research Council
(MRC) UKALL XI study most of the children with ALLDS did not display an unusual toxicity
during the course of HDMTX therapy [42]. The authors attributed this to stringent adherence
to protocols of leucovorin rescue. However, no comparison with ALLNDS children was made.
The pharmacokinetics of methotrexate in ALLDS was described by Garre et al. in a study
designed to determine the frequency and severity of MTX toxicity in five DS ALL children,
and the results were compared with NALLDS children [43]. ALLDS patients showed signifi‐
cantly higher toxicity in spite of having received relatively larger doses of leucovorin in
anticipation of higher toxicity. Gastrointestinal toxicity was the most prominent and at high
degrees (grade 2-4). Other MTX-related toxicities noted were myelosuppression up to grade
4, CNS symptoms, hepatotoxicity and maculopapular rash on skin. Repeated leucovorin in
high doses may have lessened certain incidences of high toxicity to some extent but did not
prevent toxic manifestations altogether. Furthermore, leucovorin reduced the occurrence and
severity of mucositis, the most common feature associated with MTX toxicity, in all but one
patient. In this patient, MTX doses were subsequently reduced which brought down gastro‐
intestinal and haematological toxicities to lower grade. Drug pharmacokinetics study showed
that DS patients had a greater plasma MTX concentration at 42 hours after initiating MTX
therapy in comparison to ALLNDS patients which signifies altered metabolism of the drug.
However, plasma MTX clearance did not materially vary between the two groups. A seven-
fold risk of MTX toxicity was found to be associated with ALLDS patients. This study points
to the possibility of enhanced tissue sensitivity to MTX as well as variation in drug pharma‐
cokinetics between ALLDS and ALLNDS patients. However, a recent retrospective case
controlled study of 44 ALLDS patients did not detect any clinically significant variation in the
pharmacokinetics of MTX between ALLDS and ALLNDS patients. [32]. The MTX clearance
rate was slower by 5% in ALLDS than in ALLNDS patients but the investigators did not deem
it to be of clinical importance as, at both 24 and 48 hours, the MTX plasma concentrations
between the two groups did not differ widely. As in other previous studies, this investigation
also recorded a very high number of ALLDS patients displaying grade 3-4 gastrointestinal
toxicity. The incidence of toxicity remained higher than that of ALLNDS patients even after
dose-lowering regimens were put into effect. Patients who had received doses of mercatopur‐
ine during MTX treatment did not present with any blood related toxicity. This study [32]
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strongly suggests the role of differential MTX pharmacodynamics, especially in relation to the
gastrointestinal mucous epithelium of the two patients groups, and highlights the possible
differences in the uptake and subsequent accumulation of MTX and MTX polyglutamates
(MTXPG). It seems pertinent to mention here that MTXPG remains in cells for a longer period,
and increased polyglutamation could result in cellular injury and destruction of the cells of
the intestinal mucosa. This may likely explain the exacerbated MTX toxic manifestations in
ALLDS patients [32]. Additionally, germline polymorphisms in candidate genes may play a
role in influencing the action of drug-related enzymes, proteins and drug targets, which may
subsequently contribute to enhanced MTX toxicity [44]. Children with more polymorphisms
have more gastrointestinal mucosa-related toxicity and hence may show altered pharmaco‐
dynamics [31].
The Ponte di Legno (PDL) study [22], the largest retrospective study to date, was conducted
to explore the features of ALLDS; the data of 653 ALLDS patients who were enrolled in various
international studies were analysed. It emerged that the cumulative incidence of relapse (CIR)
was higher compared to that of ALLNDS patients. Moreover, the two-year period of treatment-
related mortality (TRM) was higher in ALLNDS patients. These characteristics were seen to
have a negative impact on the eight-year event-free survival (EFS) and overall survival (OS)
of DS patients. This and several other studies compel us to further investigate the possible role
of heightened MTX toxicity and its ramifications in ALLNDS individuals with regard to
treatment outcomes, including TRM, EFS and OS. This remains a complex issue at best, as not
only the unique constitutional patient characteristics of DS but the characteristics of leukaemic
cells in the setting of DS must be considered. Additionally, interactions between MTX and
other drugs that are simultaneously given to patients may complicate the issue further.
Therefore, there appear to be multiple mechanisms and processes that regulate the response
to this drug [19]. The literature is replete with instances where, due to toxicity-related issues,
treatment protocols have been modified in which, more often than not, a reduction in MTX
dose has been made. Does it affect the natural history of disease in ALLDS patients and result
in poorer outcomes? The PDL study concluded that the largely dismal prognosis of ALLDS is
chiefly the result of a higher rate of relapses, and TRM is a less significant factor. In light of
these findings, the study does not recommend treatment reduction in general. However, for a
sub-population of patients with high hyperdiploidy or ETV6- RUNX1 mutations in which
toxicity is a leading cause of death, treatment modifications including drug reduction may be
opted [22].
The issue of dose reduction in ALLDS in the face of potential MTX toxicity has another aspect,
i.e., an overcautious approach on the part of the treating physician leads to a reluctance to use
appropriate doses of this drug. A study in DS children found that physicians used MTX and
6-mercaptopurine doses at a lesser concentration than what is prescribed in both standard
protocol treatments and is also given to ALLNDS patients [45].
Significant neurological toxicity is associated with MTX use [32]. Fortunately, most of the
symptoms are transient and resolve quickly, or resolve at least at the end of therapy [46].
However, there are several other studies that have investigated the long-term effects of MTX
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on CNS [39, 47, 48]. For ALLDS children cranial irradiation is not prescribed by any of the
cancer study groups. Therefore, in such patients the effect of chemotherapy, including
methotrexate therapy, on the CNS and its long-term sequelae remains a vital area for the
conduction of large-scale studies. As overall survival of ALLDS patients has improved, the
issue of quality of life assumes much importance. Inherently compromised brain functions
unrelated to leukaemia are a feature of DS. In this setting, coupled with a higher overall toxicity
to MTX, ALLDS children have a greater risk of chemotherapeutic insults to the brain with the
possibility of worse long-term neuropsychological sequelae including learning disabilities and
emotional problems. Intrathecal as well as intravenous MTX administration may be associated
with leukoencephalopathy, cerebral cortex atrophy and seizures [48, 49]. Furthermore, an
earlier study has reported that intrathecal cytosine arabinoside can augment the CNS toxicity
of MTX [50]. A recent study has reported the detection of extensive vascular myelopathy of
the spinal cord on an autopsy of an ALLDS patient who was given MTX therapy. The authors
suggested a possible role of MTX in the processes of white matter degeneration [51]. Krull et
al. found evidence of a direct effect of MTX on neurocognitive functions in ALL patients who
were alive ten years or more after diagnosis [47]. After controlling for cranial irradiation it was
determined that each 1gm/m2 of MTX aggravated the possibility of slowed mental processing
speed by 3% [47].
MTX administered in escalating doses with the initial dose of 100mg/m2 and gradually raising
it by 50mg/m2 without following it with folinic acid rescue, until the moment toxicity is
detected is also known as Capizzi MTX. This method is known to be associated with superior
outcomes in standard risk ALL [38]. Larsen et al. in a study compared HDMTX with leucovorin
rescue and Capizzi MTX in children, adolescents and young adults treated in accordance with
the high-risk COG ALL protocol [52]. Better EFS was reported in the HDMTX arm than in the
Capizzi MTX arm. Furthermore, fewer incidences of treatment failures including marrow and
CNS failures were observed in the HDMTX arm. In the context of ALLDS patients, the mere
extrapolation of these results may not be of much help to draw any clinically definitive
conclusion. Clearly, there is a need to conduct clinical trials involving DS patients which could
help in the way of building up a more personalized approach to treatment of DS patients.
Recently, an uncommon case has been reported of a child with ALLDS who was earlier a
patient of AML, who was treated successfully and remained in remission from AML when
ALLDS was diagnosed at four years of age. In an intensified consolidation regimen, he was
treated with an escalating dose of MTX (Capizzi MTX) given intravenously, which was not
followed by leucovorin rescue. Following the second Capizzi MTX (100mg/m2), the child
developed mucositis of moderate severity and was subsequently put on a low risk maintenance
regimen which had to be curtailed from three to two years. This modification fortunately had
no unwanted clinical effect as the child remained disease-free until the time last reported, i.e.,
at seven years post-diagnosis [30].
As in the case discussed above, and in the majority of DS patients treated with MTX, mucositis
emerged as the leading toxic manifestation. The intrinsically unique immunometabolism in
DS coupled with the rather compromised aspect of certain components of the immune system
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could also be a contributory factor in mucositis. Combined with this, the effect of MTX
metabolism in the setting of DS and enhancement in apoptosis of the mucosal cells breaches
the cellular barriers resulting in higher grades of mucositis [30]. In a study performed to explore
the metabolic and genetic components responsible for MTX toxicity, 134 childhood ALL
patients were treated in line with the DCOG-ALL-10 protocol [53], and the results showed that
MTX-associated mucositis was more common and frequent mainly after the first course of the
drug. Besides, mucositis also accounted for the major share of overall drug related toxicity (>
3). However, since the patients had neutropenia, and, prior to starting the MTX therapy, had
received drugs such as mercaptopurine, cyclophosphamide and cytarabine, the concomitant
role of these drugs in aggravating the moderately severe mucositis cannot be completely ruled
out [54, 55]. This might explain the higher toxicity at the end of first MTX course, since the
second MTX course was not preceded by these drugs. This observation raises the possibility
of interaction between drugs and their cumulative side effects, which should be further
explored in every subtype of ALL including ALLDS. Since leucovorin rescue was initiated 42
hours after the commencement of the first HDMTX dose, its detoxifying effect is most likely
to build up in the later phases of treatment and not in the starting phase, which also could have
contributed to a higher toxicity encountered during the first course. The PDL study found that
apart from reducing doses of MTX, leucovorin at a high dose was given to patients with ALLDS
by the various study groups treating ALLDS patients [22]. It is plausible that a higher leuco‐
vorin dose might interfere with the efficacy of MTX by rescuing the cancer cells in addition to
normal cells in ALLDS. This attenuation in the effect of MTX may have important implications
for therapy and therapeutic outcomes. Several studies have shown that leucovorin in higher
concentrations or its fairly early dosing after MTX administration may increase the risk of
disease relapse [56, 57]. Skarby et al. studied the associations between disease relapse, serum
methotrexate concentrations and leucovorin rescue doses in 445 children with ALL who were
treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO)
ALL92 protocol [58]. Higher leucovorin doses matched with a corresponding higher MTX
(which was determined by high serum MTX); the results indicated that the attempt to put into
effect a heightened leucovorin rescue compromised methotrexate efficacy. Disease relapse risk
was aggravated, registering a 22% increase when the leucovorin dose was doubled. This study
led to the modification in the NOPHO protocol, which then prescribed a reduction in leuco‐
vorin dose. To our knowledge, no study similar to this has been conducted in ALLDS patients;
however, since the ALLDS patients continue to be treated with minor modifications of the
existing protocols for ALLNDS this study also holds relevance for these patients. Leucovorin
doses in many instances have been intensified for ALLDS patients. Therefore, separate studies
in ALLDS patients are needed to determine the impact of higher doses of leucovorin on the
efficacy of HDMTX. Question remains about the optimum leucovorin dose that on the one
hand would keep toxicity within tolerable limits and on the other hand would not dilute the
effect of HDMTX. The enzyme dihydrofolate reductase is believed to mediate in the compet‐
itive activities of these two antagonists, i.e., MTX and leucovorin [59]. Complicating the matter
is the fact that cancer patients are prescribed folate as part of a nutrient supplementation in
order to increase appetite and reduce anorexia. This and the dietary folate may also influence
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the therapeutic effectiveness of HDMTX along with leucovorin. Studies using modern
sequencing platforms may yield further information about genetic variations in enzymatic
interactions and drugs that will aid in reaching a meticulous balance between MTX dose and
leucovorin strength. It will also lead to a more personalized approach, the significance of which
cannot be overstated in ALLDS given the heterogeneous nature of the disease [60].
The Ponte di Legno study concluded that disease relapse in ALLDS patients was the foremost
cause of inferior survival. In the light of this finding it does not recommend any reduction in
treatment except for a small minority genetic sub-group with ETV6-RUNX1 or high hyperdi‐
ploidy, where toxicity-related mortality was identified to be the highest. Interestingly, this sub-
group is also associated with the most favourable prognosis and a very low cumulative
incidence of relapse [22]. In recent years there has been a marked improvement in EFS and OS
of ALLDS children and also less disease relapse due to relatively fewer induction deaths and
treatment-related mortality as compared to the pre-2000 era [61]. This is likely in part due to
the emphasis laid upon not decreasing treatment intensity. Buitenkamp et al., for instance have
shown that usage of MTX in intermediate doses does not lead to any unexpected major toxicity
issue in ALLDS children. The authors advised that 1-3g/m2 of MTX administration coupled
with meticulous observation for any unwanted toxicity should not be unsafe as a starting
regimen [32]. Advances in supportive care for these patients might further improve the end
results of the use of chemotherapeutic drugs including MTX.
The current treatment strategies for ALLDS patients entail a modification of treatment keeping
in view the objective to limiting toxicity and minimizing treatment-related mortality. Needless
to say, this is expected to have a positive impact on disease relapse as well as on the overall
quality of life. In ALLDS patients the best practice is that MTX is intravenously administered
in the range of 500-1000mg/m2 with leucovorin rescue and no further augmentation of dose.
The other strategy is to adopt a dose escalation regimen, starting with 500mg/m2 and gradually
escalating to 2000mg/m2 (Capizzi MTX). In high-risk ALLDS patients, dose reductions of
HDMTX should not be resorted to, and Capizzi MTX administration, where protocol dictates,
should not be halted or modified in the face of apprehensions of infection. As discussed earlier,
dose reductions can be made in the favourable prognosis sub-group as well as those in which
minimal residual disease shows negative results [30].
5. Glucocorticoids
Glucocorticoids (GC) such as prednisolone and dexamethasone along with L-asparaginase
constitute an important component of therapy for all types of ALL patients, including ALLDS
patients [62]. However, usually transient hyperglycaemia has been associated with the use of
glucocorticoids and L-asparaginase and studies have indicated a synergistic role of glucocor‐
ticoids and asparaginase in the development of this condition in leukaemia patients [63]. In
ALLDS patients the risk of hyperglycaemia is compounded, which necessitates a more
thorough observation and prompt remedial measures. In the St. Jude hospital study, Pui et
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al. showed that age, obesity and DS were each linked with a higher risk of hyperglycaemia in
patients who received treatment with L-asparaginase and prednisone [64]. Additionally, in
circumstances where all these traits appear together, a combinatorial effect on glucose
intolerance could be witnessed. The authors also highlighted the relatively-increased blood
glucose levels in hyperglycaemic DS patients as compared to non-DS patients exhibiting
hyperglycaemia due to treatment [64]. Similarly, earlier studies had reported a high incidence
of non-ketotic hyperosmolar diabetic coma leading to high mortality in DS children [65, 66].
It is well established that DS patients have a greater propensity to develop diabetes mellitus,
and that too relatively earlier in life [67-69]. This has made DS an independent risk factor for
a hyperglycaemic dysmetabolic state during the course of glucocorticoid therapy in ALLDS
individuals [22]. A glucocorticoid-mediated hyperglycaemic dysmetabolic condition could be
a contributory factor in the poor prognosis associated with ALLDS patients. Altered metabo‐
lism of glucose in ALLDS leukaemia is most likely a contributory factor that influences disease
prognosis. No study in ALLDS has provided direct evidence in this regard. However, Boag et
al. showed that non-solid tumours (pre-B ALL cells) exhibit alterations in their metabolism
such as switching to exacerbated aerobic glycolysis and an increase in the number of glucose
transporter GLUT 1 [70]. The authors stated that apart from tumourigenesis, the course of
disease and its prognosis may also be associated with metabolic changes. A recent study has
shown that dexamethasone inhibited the entry and utilization of glucose and caused disrup‐
tion of glycolysis, resulting in cellular death in primary ALL blasts and ALL cell lines [71].
Furthermore, higher apoptosis was identified in those cells in which glucose concentration
was relatively low, which reveals that an efficient and higher apoptotic rate could be reached
under lower glycaemic conditions. These studies should be reproduced in ALLDS individuals
and results thus obtained would help better address the issue of hyperglycaemia in ALLDS as
altered metabolism is generally more common in DS [17, 28, 30], also, in the light of the findings
that glucocorticoid sensitivity could play a critical role in influencing treatment outcomes and
the increased resistance to these hormones could lead to a worsening prognosis. Holleman
and colleagues have described that genes related to glucose metabolism are highly expressed
in the cells resistant to glucocorticoids [72]. Notably this was detected in patients with pre-B
ALL cells, and the overwhelming majority of ALLDS belongs to the pre-B cell phenotype [18].
Moreover, enhanced glycolysis in cells exacerbates the risk for glucocorticoid resistance in
leukaemic lymphoblasts [73]. Identification and targeting of the upregulated genes and the
genetic pathways involved in the generation of higher glycolysis in DS patients in future may
prove to be advantageous.
Prednisolone and dexamethasone have both been in use in ALL for decades, especially in the
remission induction phase of therapy. However, studies have indicated better treatment
results with the use of dexamethasone, especially in the context of the higher efficacy of
dexamethasone in penetrating the blood brain barrier, leading to a lower rate of CNS relapse
[74-77] and meningeal leukaemia [78]. However, dexamethasone use is associated with a
higher drug toxicity and a higher rate of infections. Higher infections, partly as a result of
therapy causing myelosuppression, is well known in DS patients. Recently, Domenech et al.
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have shown that dexamethasone at 6mg/m2/day and prednisolone at 60mg/m2/day exert equal
benefits and that no significant variation in toxicities have been detected in the use of these
two drugs at the tested dosing [79]. However, the majority opinion seems to be that dexame‐
thasone is a better choice as far as improved CNS control is concerned. Enhanced steroid
toxicity could also manifest as myopathy and a marked increase in weight. DS individuals
independently show a predilection towards more weight gain [17]. Which of the two drugs,
dexamethasone or prednisolone, can lead to greater weight gain or exert an equal effect is a
moot question. Genetic profiling of patients in the context of glucocorticoid activities combined
with metabolomic studies may give some direction in the future. Very recently, Bindreither et
al. studied the transcriptional profile of T-ALL cells after treating them with prednisolone and
dexamethasone, which showed no remarkable variations in the transcriptional responses
detected [80]. These results also highlight that both of these glucocorticoids regulated identical
genes. Furthermore, the authors conclude that the differential treatment outcomes of dexa‐
methasone and prednisolone, as reported in several studies, are perhaps due to differences in
the pharmacokinetics and pharmacodynamics of these drugs. Studies dissecting the metabolic
and molecular pathways involved in the glucocorticoid response in DS patients will help to
inform practitioners to adjust and improve therapy. As of now, the point made by Inaba and
Pui holds relevance that, in view of the fact that considerable variations are encountered among
patients with regard to the sensitivity of ALL cells, and the same for glucocorticoid toxicity,
best practice would be to consider the risk of relapse, phase of therapy and the drugs that are
administered concomitantly with the glucocorticoids, before opting for a particular glucocor‐
ticoid [62]. Currently, in delayed intensification therapy for ALLDS patients, MRC UK and
COG cancer groups recommend discontinuous dexamethasone dosing [18, 30].
6. Anthracyclines and Cytarabine (Ara –C)
Anthracyclines, mainly daunorubicin, doxorubicin and idarubicin, are used in the therapeutic
regimens for treating ALL as well as AML [15, 81]. These anti-tumour antibiotics bind to DNA
and prevent the unwinding activity of topoisomerase, which leads to abrogation of the process
of DNA replication. Cytarabine (ara-C) incorporates into DNA through its active metabolite
and impedes the binding of d-CTP to DNA. It abrogates the activity of the DNA polymerase
enzyme [28]. In current treatment strategies, ara-C has taken the central stage for AML
treatment, including AMLDS.
In ALLDS patients, anthracycline use is advocated differently by the groups. The Dutch
Children Oncology Group (DCOG) and France Acute Lymphoblastic Leukaemia (FRALLE)
do not use anthracyclines for induction therapy at all, whereas, daunorubicin induction is
given by some groups in the case of patients with inadequate response. Anthracycline, along
with glucocorticoids were given in the induction phase by physicians at St. Jude Research
Hospital, fortunately with no reported unexpected toxicities. For further improvement in
survival and lowering toxicities especially cardiac toxicity, further trials and research studies
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are greatly needed so that the optimum balance of modern therapy can be reached in the
different risk groups of patients with ALLDS [18].
Several studies have been conducted in AMLDS patients to determine the effects, side effects
and efficacy of anthracycline, which also highlights the altered drug response and unique
genetic and metabolic make up of AMLDS individuals. Unlike ALLDS, AMLDS children have
a better outcome with the highest curative rate of any other group of myeloid leukaemia
patients [16, 82, 83]. The French American British Classification (FAB) classification AML M7
is characterized by one of the worst prognoses in children without DS. However, the situation
is different in the context of acute megakaryoblastic leukaemia (AMkL) DS, especially in
children younger than three years of age, where excellent prognosis in recent years has
generally been acknowledged [18, 84]. AMkL happens to be the most common phenotype in
AMLDS [19].
Increased sensitivity to anthracycline and other drugs can be attributed to the presence of a
high level of oxygen free radicals which are inherent in the cellular constituents of DS indi‐
viduals [28, 85]. The enhanced ROS production coupled with perturbation in superoxide
dismutase observed in DS, in the absence of concomitant increase in other antioxidant enzymes
such as catalase and glutathione peroxidase, predisposes the cells to undergo apoptosis. In this
altered metabolic state, drug-induced apoptosis is further exaggerated. It has been proposed
that the HAS 21-linked gene dosage effect of NADH dehydrogenase ubiquinone flavoproein
3 may be responsible for increased ROS production through enhanced mitochondrial respi‐
ration [84]. Reduced anthracycline dosage is now universally prescribed for AMLDS patients,
especially to obviate the well-known cardiotoxicity associated with anthracycline therapy. This
is particularly beneficial to DS individuals as they are prone to mitochondrial dysfunction and
thereby increased cardiac oxidative stress [86].
The well-known favourable prognosis in AMLDS children reflects the enhanced sensitivity of
leukaemic blasts to cytarabine (ara-C) and anthracyclines [87-89]. The modification of cancer
drug metabolism including ara-C in AMLDS individuals has been the subject of extensive
research. A landmark study by Taub et al. found that DS myeloblasts showed an enhanced
sensitivity to ara-C, which was ascribed as being a contributory factor to better prognosis. This
is further supported by the observations that both DS myeloblasts as well as trisomy 21
lymphoblastoid cell lines accumulate higher ara-CTP (a metabolite of ara-C synthesis) levels
than non-DS cells. Taken together, these observations imply an altered metabolism of ara-C in
DS children. However, other factors like the concomitant use of daunorubicin or the gene
dosage effect of enzymes related to chromosome 21 such as carbonyl reductase and superoxide
dismutase (SOD) may also influence outcomes in AMLDS patients [16]. Zwaan et al. showed
that AMLDS cells were 12 times more sensitive to ara-C than AMLNDS cells [89]. The authors
also determined a two- to seven-fold heightened anthracycline sensitivity in AMLDS cells. In
another study, AMLDS cells showed a several-fold increase in sensitivity to both ara-C and
daunorubicin in MTT drug assays. Besides, a remarkably higher concentration of ara-CTP was
also detected, which strongly pointed to a link between trisomy 21 and high drug sensitivity
[90]. Other studies have strengthened this view and implicate an altered metabolism of both
ara–C and daunorubicin in AMLDS children [88, 89].
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Mutations in the GATA1 transcription factor gene present on chromosome X is an exclusive
feature of AMkLDS [29]. These mutations likely contribute to augmented ara-C sensitivity.
GATA1 mutants were found to have a truncated 40 KDa protein in AMLDS blasts instead of
the wild-type 50 KDa protein [29]. This affects cytidine deaminase (CDA) gene expression,
which is believed to result in less CDA expression in DS myeloid blasts, accounting for the
increased ara-C sensitivity. Another factor that might play a role in increased ara-C sensitivity
is the alteration in folate metabolism, which is traced to the heightened activity of the CBS
enzyme linked to HSA21.
7. Future directions in pharmacotherapy
With an increased longevity of DS individuals, new challenges have arisen in the area of the
management and treatment of associated morbidities. An increasing age carries the potential
to modify the natural history of the disease. Additionally, in DS the phenomenon of accelerated
ageing, and thereby accompanied changes in metabolism, is a factor that can hardly be ignored.
A better understanding of drug metabolism in DS is extremely useful because DS individuals
receive several medicines as part of their palliative care and to combat concomitant illnesses.
Further collaborative studies in a larger DS cohort are warranted to better understand the
phenomenon of altered drug metabolism and concomitant drug interactions. DS is character‐
ized by phenotypic heterogeneity, and the varying severity and complexity of the disease
involves multi-organ systems. Given the wide spectrum of clinical anomalies in DS, future
pharmacotherapy approaches need a more tailored approach for personalized medicine based
on advanced knowledge and input from drug metabolism studies in DS individuals. Thus,
further research and information from case studies and drug trials are warranted to adopt
appropriate treatment regimes. It may also be relevant to neurodegenerative diseases such as
dementia and Alzheimer’s, which have an earlier onset in DS and are also prevalent in a large
proportion of elderly people in the general population.
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